These data suggest that prolactinomas with failure to achieve normalization of PRL levels, together with no size regression, by 12 months may be considered for alternative management strategies, as recommended by most recent guidelines and consensus statements (8, 9). The gene discussed is PRL; the disease is prolactin-producing pituitary gland adenoma.